BR0007727A - Composto, processo para preparar os compostos,método para inibir mudanças patológicas mediadaspela enzima que converte o tnf-alfa (tace) em ummamìfero em necessidade deste, e, composiçãofarmacêutica - Google Patents

Composto, processo para preparar os compostos,método para inibir mudanças patológicas mediadaspela enzima que converte o tnf-alfa (tace) em ummamìfero em necessidade deste, e, composiçãofarmacêutica

Info

Publication number
BR0007727A
BR0007727A BR0007727-5A BR0007727A BR0007727A BR 0007727 A BR0007727 A BR 0007727A BR 0007727 A BR0007727 A BR 0007727A BR 0007727 A BR0007727 A BR 0007727A
Authority
BR
Brazil
Prior art keywords
compounds
tace
enzyme
alpha
compound
Prior art date
Application number
BR0007727-5A
Other languages
English (en)
Inventor
Jeremy Ian Levin
James Ming Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0007727A publication Critical patent/BR0007727A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)

Abstract

"COMPOSTO, PROCESSO PARA PREPARAR OS COMPOSTOS, MéTODO PARA INIBIR MUDANçAS PATALóGICAS MEDIADAS PELA ENZIMA QUE CONVERTE O TNF-alfa (TACE) EM UM MAMìFERO EM NECESSIDADE DESTE, E, COMPOSIçãO FARMACêUTICA". Compostos da fórmula (B) ou (1b), (1c): são fornecidos em que as variáveis são como aqui definidas, que são úteis em condições de doença mediadas pelo TNF-(, tais como na artrite reumatóide, osteoartrite, sépsia, AIDS, colite ulcerativa esclerose múltipla, Doença de Crohn e perda degenerativa de cartilagem.
BR0007727-5A 1999-01-27 2000-01-27 Composto, processo para preparar os compostos,método para inibir mudanças patológicas mediadaspela enzima que converte o tnf-alfa (tace) em ummamìfero em necessidade deste, e, composiçãofarmacêutica BR0007727A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23839399A 1999-01-27 1999-01-27
PCT/US2000/002143 WO2000044716A1 (en) 1999-01-27 2000-01-27 Acetylenic sulfonamide thiol tace inhibitors

Publications (1)

Publication Number Publication Date
BR0007727A true BR0007727A (pt) 2001-10-30

Family

ID=22897697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007727-5A BR0007727A (pt) 1999-01-27 2000-01-27 Composto, processo para preparar os compostos,método para inibir mudanças patológicas mediadaspela enzima que converte o tnf-alfa (tace) em ummamìfero em necessidade deste, e, composiçãofarmacêutica

Country Status (21)

Country Link
EP (1) EP1149074B1 (pt)
JP (1) JP2002535386A (pt)
KR (1) KR20010101691A (pt)
CN (1) CN1224612C (pt)
AT (1) ATE280152T1 (pt)
AU (1) AU766192B2 (pt)
BR (1) BR0007727A (pt)
CA (1) CA2356480A1 (pt)
CZ (1) CZ20012545A3 (pt)
DE (1) DE60015079T2 (pt)
DK (1) DK1149074T3 (pt)
EA (1) EA200100811A1 (pt)
ES (1) ES2230064T3 (pt)
HK (1) HK1038915A1 (pt)
HU (1) HUP0105282A3 (pt)
IL (1) IL144347A0 (pt)
NO (1) NO20013638L (pt)
NZ (1) NZ512306A (pt)
PL (1) PL350420A1 (pt)
WO (1) WO2000044716A1 (pt)
ZA (1) ZA200105069B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033477A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
DE60232276D1 (de) 2001-12-20 2009-06-18 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta-amyloidinhibitoren
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194209T3 (es) * 1996-07-22 2003-11-16 Monsanto Co Inhibidores de metaloproteasa de tiol sulfona.
NZ333825A (en) * 1996-07-22 2000-10-27 Monsanto Co Metalloprotease inhibitors particularly MMP-13

Also Published As

Publication number Publication date
HUP0105282A3 (en) 2005-04-28
HUP0105282A2 (hu) 2002-05-29
HK1038915A1 (zh) 2002-04-04
EP1149074A1 (en) 2001-10-31
AU766192B2 (en) 2003-10-09
CA2356480A1 (en) 2000-08-03
DK1149074T3 (da) 2005-01-10
NZ512306A (en) 2003-10-31
WO2000044716A1 (en) 2000-08-03
NO20013638D0 (no) 2001-07-24
KR20010101691A (ko) 2001-11-14
DE60015079T2 (de) 2005-03-03
AU2741700A (en) 2000-08-18
NO20013638L (no) 2001-07-24
CN1337947A (zh) 2002-02-27
PL350420A1 (en) 2002-12-16
CZ20012545A3 (cs) 2002-04-17
ZA200105069B (en) 2002-09-20
ES2230064T3 (es) 2005-05-01
EA200100811A1 (ru) 2002-12-26
EP1149074B1 (en) 2004-10-20
JP2002535386A (ja) 2002-10-22
IL144347A0 (en) 2002-05-23
ATE280152T1 (de) 2004-11-15
DE60015079D1 (de) 2004-11-25
CN1224612C (zh) 2005-10-26

Similar Documents

Publication Publication Date Title
BR0007752A (pt) Composto, processo para preparar o mesmo,método de inibir mudanças patológicas mediadaspela enzima que converte tnf-"alfa" (tace) em ummamìfero em necessidade deste, e, composiçãofarmacêutica
BR0007727A (pt) Composto, processo para preparar os compostos,método para inibir mudanças patológicas mediadaspela enzima que converte o tnf-alfa (tace) em ummamìfero em necessidade deste, e, composiçãofarmacêutica
BR0007783A (pt) Composto, método de inibir mudanças patológicas mediadas pela enzima que converte o tnf-a (tace) em um mamìfero em necessidade deste, composição farmacêutica, e, processos para preparar um composto
ES2246227T8 (es) Moléculas de ácido nucleico que codifican alternansacarasa
BR9602187A (pt) Processo de inibir a corrosão por ácido naftênico em um sistema de hidrocarboneto a alta temperatura
KR840006812A (ko) 해중합된 과황산염 헤파린의 제조방법
NO940595L (no) Cykliske derivater, legemidler som inneholder disse forbindelsene og fremgangsmåte ved deres fremstilling
BR0013130A (pt) Composições para controlar cescimentos biológico e macrobiológico em fluidos industriais, e, processos para controlar crescimentos biológico e macrobiológico em um fluìdo industrial
EA200100533A1 (ru) Производные эритромицина, способ их получения и их применение в качестве лекарственных средств
NZ511885A (en) 2,3,4,5-tetrahydro-1H-[1,4]benzodiazephine-3-hydroxamic acid as matrix metalloproteinase inhibitors and as inhibitors of TNF-alpha converting enzyme (TACE)
ATE209187T1 (de) Fluorinierte 2-nitroimidazole analoge zur detektion von hypoxischen tumorzellen
BR9915886A (pt) Composto, composição farmacêutica, e, método para tratar um mamìfero com uma condição relacionada com a inflamação
EA200001152A1 (ru) СУКЦИНАМИДНЫЕ ИНГИБИТОРЫ ИНТЕРЛЕЙКИН - 1b - КОНВЕРТИРУЮЩЕГО ФЕРМЕНТА
BR8606843A (pt) Processo para obter-se um anidrido e/ou acido substituido por hidrocarbila
BR9714066A (pt) Processo para a preparação de derivados de tiazol.
DE3369685D1 (en) One-package, heat-curable compositions suitable for use as sealants, solid coatings and moldings
BR0007750A (pt) Composto, processo para preparar o mesmo,método para inibir mudanças patológicas mediadaspela enzima que converte o tnfalfa (tace) em ummamìfero com necessidade desta, e, composiçãofarmacêutica
ES522984A0 (es) Procedimiento de preparacion de un acido halogenobenzhidrilsulfinilacetohidroxamico.
BR0007754A (pt) ácido de hidroxamida, processo para preparar osmesmos, composto, método de inibir mudançaspatológicas mediadas pela enzima que converte atnf-alfa (tage) em mamìfero em necessidade deste,e, composição farmacêutica
BR0007760A (pt) Composto, processo para preparar o mesmo,método para inibir mudanças patológicas mediadaspela enzima que converte o tnf-alfa (tace) em ummamìfero em necessidade deste, método paratratar um paciente que sofre de uma condição, e,composição farmacêutica
BR0007726A (pt) Composto, processo para preparar o mesmo,método de inibir mudanças patológicas, e,composição farmacêutica.
EA199900528A1 (ru) Новые производные эритромицина, способ их получения и применения в качетве медикаментов
ES8200922A1 (es) Procedimiento para preparar kijanimicina
FR2720393B1 (fr) Réactif utile pour et procédé pour la synthèse d'ester et xanthate transestérifiable.
ES8504186A1 (es) Un procedimiento para preparar un compuesto de b-lactama monociclica (4r)-sustituida opticamente activa

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.